Related Experiment Video
Updated: Mar 16, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer
H H Gari1, G D DeGala1, M S Lucia1
1Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Abstract:
Stimulating tumor cell senescence and apoptosis are proven methods for therapeutically combating cancer. However, senescence and apoptosis are conventionally viewed as parallel, not sequential, processes. We have discovered that the metastasis-promoting phosphatase, PRL-3, is transcriptionally regulated by the NF-ĸB pathway in triple-negative breast cancer (TNBC) cells, and that PRL-3 knockdown elicits an autocrine tumor necrosis factor receptor 1 (TNF-R1) feedback loop that results in TNBC cell senescence followed by apoptosis. Knockdown of PRL-3 leads to rapid G1 cell cycle arrest and induction of a strong TNFα cytokine response that promotes a period of cellular senescence through TNF-R1-mediated activation of NF-ĸB. Senescent PRL-3 knockdown cells subsequently underwent apoptosis as a result of increased TNF-R1 signaling through the TNFα-associated extrinsic death pathway, shunting signaling away from the NF-ĸB cascade. These data suggest that TNF-R1 signaling dynamically re-programs after PRL-3 knockdown, from sustaining cell senescence through NF-ĸB to promoting apoptosis through TNF-R1 internalization and caspase-8 activation. The molecular mechanisms that determine the survival-death balance of TNF-R1 signaling are poorly understood, despite the fact that TNF-R1 has been extensively studied. Our results describe PRL-3 knockdown as a novel survival-death balance modifier of the TNF-R1 pathway, and show that senescent TNBC tumor cells can be sensitized to undergo apoptosis in a sequential manner.
Insights
Discovering a new sequential cancer therapy: Knocking down PRL-3 in triple-negative breast cancer (TNBC) cells induces senescence then apoptosis via a TNF-R1 feedback loop, offering a novel therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Cancer therapies often target tumor cell senescence and apoptosis.
- Senescence and apoptosis are typically considered parallel, not sequential, processes.
- The role of PRL-3 in triple-negative breast cancer (TNBC) and its regulation by NF-κB are key areas of investigation.
Purpose of the Study:
- To investigate the role of PRL-3 in TNBC.
- To elucidate the sequential relationship between senescence and apoptosis in TNBC.
- To explore the mechanism of PRL-3 knockdown-induced cell death.
Main Methods:
- Utilized knockdown of PRL-3 in TNBC cells.
- Analyzed cell cycle arrest, cytokine response (TNFα), and cell death pathways.
- Investigated the involvement of NF-κB and TNF-R1 signaling pathways.
Main Results:
- PRL-3 knockdown in TNBC cells triggers an autocrine TNF-R1 feedback loop.
- This leads to sequential TNBC cell senescence followed by apoptosis.
- TNF-R1 signaling dynamically shifts from NF-κB-mediated senescence to caspase-8-mediated apoptosis.
Conclusions:
- PRL-3 knockdown represents a novel strategy to modify the TNF-R1 pathway's survival-death balance.
- Senescent TNBC cells can be sequentially sensitized to undergo apoptosis.
- This study reveals a novel mechanism for inducing sequential cell death in cancer therapy.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation

